benzylthiotributylstannane | 23728-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzylthiotributylstannane
• 英文别名: benzyl(tributyltin) sulfide；Tri-n-butylzinnbenzylmercaptid；(n-C4H9)3SnSCH2C6H5；phenyl-methanethiol; dibutyl tin bis-phenylmethanethiolate；Phenyl-methanthiol; Dibutylzinn-bis-phenylmethanthiolat；n-tributylstannyl-sulfanylmethyl-benzene；tributyl[(phenylmethyl)thio]stannane；tributyltin benzylthiolate；Phenylmethanethiolate;tributylstannanylium
• CAS: 23728-85-0
• 化学式: C₁₉H₃₄SSn
• 分子量: 413.255
• InChiKey: DWZDMTKSHGBFKM-UHFFFAOYSA-M

物化性质

• 沸点：
  165 °C(Press: 0.1 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  7.27
• 重原子数：
  21
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  benzylthiotributylstannane 、 苯甲酰氯 以 氯仿 为溶剂， 生成 硫代苯甲酸苄酯
  参考文献：
  名称：

  从有机锡硫醇盐和酰氯轻松制备硫醇酯

  摘要：

  有机锡硫醇盐与酰氯缩合，以优异的收率得到硫醇酯。值得注意的是-丁基和苯基硫醇酯的有效合成。

  DOI：

  10.1016/s0040-4039(01)86433-9
• 作为产物：
  描述：

  苄硫醇 、 三丁基氯化锡 以90%的产率得到
  参考文献：
  名称：

  HARPP D. N.; AIDA T.; CHAN T. H., TETRAHEDRON LETT., 1979, NO 31, 2853-2856

  摘要：

  DOI：
• 作为试剂：
  描述：

  溴己烷 在 TBA-CN 、 benzylthiotributylstannane 作用下， 以 乙腈 为溶剂， 反应 2.3h， 以84%的产率得到benzyl(hexyl)sulfane
  参考文献：
  名称：

  氰基和氟去甲锡烷基化：使用一些强大的硫转移试剂，即有机锡硫化物的新方法

  摘要：

  氟化物和氰化物离子destannylate双（芳烷基）锡硫化物[R 3 SnSSnR 3 ]和三烷基锡硫化物[R 3 SnSR'（R =烷基）]给出，在多种烷基的存在和活化的卤化物，相应的硫醚衍生物，收率极高。条件温和，中性和无水；注意到强烈的溶剂作用。对后处理程序提出了特别的意见。

  DOI：

  10.1016/s0040-4039(00)96513-4

文献信息

• [EN] CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN<br/>[FR] CHLOROTHIOPHÈNE-AMIDES UTILISÉS COMME INHIBITEURS DES FACTEURS DE COAGULATION XA ET DE LA THROMBINE
  申请人：SANOFI AVENTIS

  公开号：WO2009103440A1

  公开（公告）日：2009-08-27

  The present invention relates to compounds of the formula I wherein R1; R2; R3; R4; R5, R13, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and thrombin and can in general be applied in conditions in which an undesired activity of factor Xa and/or thrombin are present or for the cure or prevention of which an inhibition of factor Xa and thrombin are intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及具有式I的化合物，其中R1; R2; R3; R4; R5, R13, R16, X和M具有权利要求中所指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强大的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和凝血酶的可逆抑制剂，通常可应用于存在因子Xa和/或凝血酶不良活性的情况，或者用于治疗或预防需要抑制因子Xa和凝血酶的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants
  申请人：——

  公开号：US20030207920A1

  公开（公告）日：2003-11-06

  Compounds of formula [I] 1 in which: W may represent a —(CH 2 ) 2 —, —(CH 2 ) 3 —, —CH 2 —C≡C— or —CH 2 —CH═CH— group, R 2 may in particular represent a piperidyl group, an optionally substituted 1,2,3,6-tetrahydropyridyl group, a hexahydro-1H-azepinyl group, an optionally substituted piperazinyl group or a morpholinyl group, R 3 may in particular represent a group —COR 1 , A may in particular represent an optionally substituted phenyl group, a heterocycle or a cyclopentyl group, and B may in particular represent a pyridyl group, an aminopyrazinyl group, an aminopyridazinyl group, a pyrimidinyl group optionally substituted with an amino group, piperidyl group or an aminopyridyl group optionally substituted on the pyridine with a (C 1 -C 4 )alkyl or (C 1 -C 4 )alkoxy group, the amino group possibly also being substituted with a (C 1 -C 4 )alkyl group, their preparation and their therapeutic application.

  式为[I]1的化合物中：W可以代表一个—(CH2)2—、—(CH2)3—、—CH2—C≡C—或—CH2—CH═CH—基团，R2特别可以代表哌啶基团、一个可选择地取代的1,2,3,6-四氢吡啶基团、一个六氢-1H-氮杂环庚基团、一个可选择地取代的哌嗪基团或吗啉基团，R3特别可以代表一个—COR1基团，A特别可以代表一个可选择地取代的苯基团、一个杂环或一个环戊基团，B特别可以代表一个吡啶基团、一个氨基吡嗪基团、一个氨基吡啶基团，一个可选择地取代的嘧啶基团，该嘧啶基团上可选择地取代有氨基、哌啶基团或可选择地取代的苯基团，该氨基团还可能被(C1-C4)烷基或(C1-C4)烷氧基取代，它们的制备及其治疗应用。
• Construction of the carbon–chalcogen (S, Se, Te) bond at the 2,6-positions of BODIPY via Stille cross-coupling reaction
  作者：E. Palao、T. Slanina、P. Klán

  DOI：10.1039/c6cc06923a

  日期：——

  Novel 2-chalcogen- or 2,6-dichalcogen-BODIPY derivatives were synthesized by a Pd-catalyzed C-heteroatom Stille cross-coupling reaction, overcoming the limitations of SNAr.

  通过Pd催化的C-杂原子Stille交叉偶联反应合成了新型的2-硫属元素或2,6-二卤代-BODIPY衍生物，克服了S N Ar的局限性。
• Transition metal mediated thiation of aromatic rings
  作者：Michael J. Dickens、John P. Gilday、Timothy J. Mowlem、David A. Widdowson

  DOI：10.1016/s0040-4020(01)82405-4

  日期：1991.9

  Three approaches to aromatic thiation have been studied. Dependent upon access to the necessary starting material, displacement of halogen in haloarenetricarbonylchromium(0) complexes by nucleophilic sulphur, quenching of lithiated arenetricarbonylchromium(0) complexes by electrophilic sulphur or palladium catalysed cross coupling of aryl iodides with alkylthiotrialkylstannanes were all effective and

  研究了三种芳族硫杂化方法。取决于获得必要原料的可能性，亲核硫取代卤代芳基三羰基铬（0）络合物中的卤素，亲电硫或钯催化的芳基碘化物与烷基硫代三烷基锡烷的交叉偶联猝灭锂化的芳基羰基铬（0）络合物都是有效的，并且显然在一般情况下范围。后者是首选过程。
• 5-Chlorothiophene-2-carboxylic Acid [(<i>S</i>)-2-[2-Methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a Selective and Potent Orally Active Dual Thrombin and Factor Xa Inhibitor
  作者：Jerome Meneyrol、Markus Follmann、Gilbert Lassalle、Volkmar Wehner、Guillaume Barre、Tristan Rousseaux、Jean-Michel Altenburger、Frederic Petit、Zsolt Bocskei、Herman Schreuder、Nathalie Alet、Jean-Pascal Herault、Laurence Millet、Frederique Dol、Peter Florian、Paul Schaeffer、Freddy Sadoun、Sylvie Klieber、Christophe Briot、Françoise Bono、Jean-Marc Herbert

  DOI：10.1021/jm4005835

  日期：2013.12.12

  Compound 15 (SAR107375), a novel potent dual thrombin and factor Xa inhibitor resulted from a rational optimization process. Starting from compound 14, with low factor Xa and modest anti-thrombin inhibitory activities (IC50's of 3.5 and 0.39 mu M, respectively), both activities were considerably improved, notably through the incorporation of a neutral chlorothiophene PI fragment and tuning of P2 and P3-P4 fragments. Final optimization of metabolic stability with microsomes led to the identification of 15, which displays strong activity in vitro vs factor Xa and thrombin (with K-i's of 1 and 8 nM, respectively). In addition 15 presents good selectivity versus related serine proteases (roughly 300-fold), including trypsin (1000-fold), and is very active (0.39 mu M) in the thrombin generation time (TGT) coagulation assay in human platelet rich plasma (PRP). Potent in vivo activity in a rat model of venous thrombosis following iv and, more importantly, po administration was also observed (ED50 of 0.07 and 2.8 mg/kg, respectively). Bleeding liability was reduced in the rat wire coil model, more relevant to arterial thrombosis, with 15 (blood loss increase of 2-fold relative to the ED80 value) compared to rivaroxaban 2 and dabigatran etexilate 1a.